Ashley Chan

Ashley Chan joined the OncLive team as an assistant editor in 2025 after previously working on the CURE editorial team since 2023.

Email: achan@mjhlifesciences.com

Articles

Dr McLornan on the Challenges of Identifying Optimal Timing for Transplantation in Myelofibrosis

April 18th 2025

Donal McLornan, MBBCh, MRCP, PhD, FRCPath, explains the challenges of choosing optimal timing for allogeneic hematopoietic cell transplantation in myelofibrosis.

Dr Richardson on the Role of Quadruplet Regimens in Newly Diagnosed Myeloma

April 17th 2025

Paul G. Richardson, MD, discusses 2 quadruplet regimens for the treatment of patients with newly diagnosed multiple myeloma and changes in administration.

Encorafenib/Cetuximab Plus mFOLFOX6 Provides New SOC for BRAF V600E+ mCRC

April 16th 2025

Scott Kopetz, MD, PhD, FACP, highlights the efficacy of encorafenib/cetuximab with mFOLFOX6 in BRAF V600E–mutated metastatic colorectal cancer.

Dr Opat on the Unique Mechanism of Action of Sonrotoclax in R/R CLL

April 16th 2025

Stephen Opat, MBBS, explains the unique mechanism of action of sonrotoclax and how it differs from venetoclax for the treatment of patients with relapsed/refractory CLL or SLL.

FDA-Approved Isotope Therapies Provide 2 Options in the Castration-Resistant Prostate Cancer Armamentarium

April 15th 2025

Yung Lyou, MD, discusses FDA-approved isotope therapies and the development of novel therapies in the castration-resistant prostate cancer space.

PARP Inhibitor Rechallenge With Niraparib Plus Bevacizumab Is Feasible, Active in Recurrent Ovarian Cancer

April 15th 2025

Hyun-Woong Cho, MD, PhD, highlights the efficacy of niraparib/bevacizumab as maintenance therapy in platinum-sensitive, recurrent ovarian cancer.

Dr Nguyen on Treatment Selection Considerations for Non–Clear Cell RCC

April 15th 2025

Charles B. Nguyen, MD, details treatment selection in clinical practice for patients with non–clear cell renal cell carcinoma.

Apalutamide Boosts 24-Month OS in Real-World Population With Metastatic Castration-Sensitive Prostate Cancer

April 14th 2025

Apalutamide reduced the risk of death by over 20% vs enzalutamide and abiraterone acetate, respectively, in metastatic castration-sensitive prostate cancer.

Temsirolimus/Metformin Combo Generates Forward-Looking Questions in Endometrial Cancer

April 14th 2025

Pamela T. Soliman, MD, MPH, discusses a phase 1 investigation of temsirolimus plus metformin in patients with recurrent endometrial cancer.

Dr Somaiah on Overcoming Challenges to Multidisciplinary Approaches in Sarcoma

April 11th 2025

Neeta Somaiah, MD, details challenges that are associated with pathology diagnosis, NGS, and early opinions for patients with sarcomas.

Early Infection Incidence After Cilta-Cel Shows Importance of Toxicity Monitoring in Myeloma

April 11th 2025

Early infection risk following cilta-cel infusion in patients with multiple myeloma emphasizes the importance of monitoring for treatment-emergent infections.

Multidisciplinary BiTE-Associated AE Education Increases the Safety of Outpatient Administration

April 10th 2025

Educating patients and health care providers about BiTE-associated CRS and ICANS increases comfort levels with giving these agents in outpatient settings.

Dr Ahmed on the Rationale for Evaluating NTKR-255 After CAR T-Cell Therapy in R/R LBCL

April 10th 2025

Sairah Ahmed, MD, explains the rationale for evaluating NTKR-255 after CAR T-cell therapy in relapsed/refractory large B-cell lymphoma.

Antidiarrheal Medication Is Crucial for Mitigating NALIRIFOX-Related Diarrhea in Metastatic PDAC

April 10th 2025

Diarrhea is common in patients with PDAC treated with NALIRIFOX and can be proactively managed or mitigated to potentially improve survival outcomes.

FDA Greenlights Bevacizumab Biosimilar in Multiple Solid Tumor Indications

April 10th 2025

The bevacizumab biosimilar Jobevne was approved by the FDA for the treatment of several solid tumor types, including mCRC, NSCLC, and RCC.

Dr Escobar on CDK4/6 Inhibitor Selection in HR+ Metastatic Breast Cancer

April 9th 2025

Mauricio Escobar, MD, discusses CDK4/6 inhibitor selection based on retrospective real-world analyses in HR-positive metastatic breast cancer.

Dr Shah on the Clinical Implications and Future Directions of Zamto-Cel in R/R DLBCL

April 8th 2025

Nirav Shah, MD, discusses the clinical implications and future directions for zamto-cel in patients with relapsed/refractory diffuse large B-cell lymphoma.

Dual PD-1/CTLA-4 Inhibition With Cadonilimab Plus Lenvatinib Yields Disease Control in Advanced Endometrial Cancer

April 8th 2025

Chunyan Lan, MD, PhD, details the efficacy and safety of cadonilimab/lenvatinib in platinum-pretreated advanced endometrial cancer.

R-DA-EDOCH/R-DHAP Induction Yields Responses and MRD Negativity in Young, High-Risk MCL Population

April 8th 2025

Induction R-DA-EDOCH/R-DHAP therapy yields high rates of CR, overall response, and MRD negativity in young patients with newly diagnosed, high-risk MCL.

Dr Zhang on the Rationale of Evaluating SIM0270/Everolimus in ER+/HER2– Advanced Breast Cancer

April 7th 2025

Jian Zhang, MD, details the rationale of evaluating SIM0270 plus everolimus in patients with ER-positive/HER2-negative advanced breast cancer.